Pasteur acquires Shantha Biotechnics
French company, Sanofi-aventis will acquire Mérieux
Alliance’s French subsidiary ShanH, which owns a majority
stake in vaccine company Shantha Biotechnics based in Hyderabad. Alain
Mérieux, chairman of Merieux Alliance, will chair the board
of ShanH and a new joint committee will be created to chalk out vaccine
strategy for the emerging markets.
Under the terms of the agreement, Sanofi Pasteur, the vaccines division
of the Sanofi-aventis Group, will support Shantha’s ongoing
development to address the need for high quality affordable vaccination
in international markets. Dr Varaprasad Reddy, the founder of Shantha
Biotechnics, will continue to lead the company as the managing director.
Commenting on the agreement, Christopher A Viehbacher, CEO,
Sanofi-aventis, said, “Shantha provides Sanofi Pasteur with a
portfolio of new vaccines in development which complement Sanofi
Pasteur’s current vaccines portfolio to accelerate its growth
in strategically important emerging markets. The state-of-the-art
manufacturing facilities allow Sanofi Pasteur to gain high quality
capacity and enable us to provide important vaccines at affordable
prices to many people around the world. Our commitment to this
objective is highlighted by the creation of a new strategic committee
which will be chaired by Alain Mérieux.”
Alain Mérieux, chairman, Mérieux Alliance said,
“In the last three years, with the support of
Shantha’s founder, Dr Varaprasad Reddy, we have significantly
developed our company. We have refocused its activity on vaccines and
strengthened its range of products, especially by successfully
launching a pentavalent pediatric vaccine as well as a cholera vaccine.
We have built up a portfolio of new products including rotavirus
vaccine, conjugated typhoid vaccine and HPV vaccine.”
Shantha works with supranational organizations like UNICEF and PAHO to
supply vaccines to major international markets like
Asia-Pacific, Africa and Latin America.
gets EU approvals for GM Corn
Monsanto Company announced that experts at the European Food Safety
Authority (EFSA), have issued a favorable scientific opinion on
Monsanto’s Roundup Ready 2 corn product for cultivation and
reconfirmed the safety of its YieldGard insect-protected corn trait.
In its opinion, EFSA confirmed that the product, also known as MON 810,
is safe for cultivation, animal feed and human consumption. The
in-depth safety review of the YieldGard insect-protected corn borer
technology, which protects corn plants from the devastating effects of
the European corn borer insect, is required every 10 years. The
original review and approval of MON 810 in the European Union occurred
in 1998. The extensive scientific review considered all of the new
safety studies conducted since then.
Monsanto has also been expanding its seeds and traits portfolio to
include wheat with the acquisition of WestBred, a Montana-based company
that specializes in wheat germplasm, the crop’s seed genetic
material. The investment will bolster the future growth of
Monsanto’s seeds and traits platform and allow farmers to
benefit from the company’s experience in drought, disease and
Q1 revenue surges 83% to Rs 505 crore
Biocon has announced its financial performance for the three months
ended June 30, 2009. The consolidated revenues (including
German subsidiary, AxiCorp) jumped 83% from Rs 277 crore in FY 2009 to
Rs 505 crore in FY 2010.
Financial performance excluding AxiCorp also delivered strong numbers:
revenues increased 14% to Rs 316 crore, operating profits grew 45% to
Rs 101 crore and PAT jumped 261% to Rs 54 crore. While operating
margins (excluding AxiCorp) were sustained at 32%. AxiCorp has
delivered good performance in the period under review
registering a top line of Rs190 crore whilst delivering an
operating profit of Rs 11 crore and a PAT of Rs 4 crore.
Syngene and Clinigene continued to grow robustly delivering a 50%
growth in revenues to touch Rs 64 crore and a 169% spurt in operating
profits (Rs 25 crore). PAT increased to Rs 7 crore, a 133%
growth over the previous year.
Biocon has recently announced a strategic partnership with a global
generics pharma company, Mylan, to develop a basket of generic
biologics which are expected to deliver the next bolus of high margin
growth for the global pharmaceutical generics industry.
initiates carbon footprint reduction
Millipore Corporation, the company providing technologies, tools and
services for bioscience research and biopharmaceutical manufacturing,
is in the midst of a global sustainability initiative, an
effort aimed at reducing the company’s environmental impacts
and carbon footprint by 20 percent over the next five years.
Millipore’s sustainability initiative encompasses a range of
programs focused on reducing the company’s consumption of
non-renewable resources, eliminating waste and adopting behavioral
changes that support long-term environmental sustainability. Many of
these programs are aimed at substantially reducing
Millipore’s contribution to greenhouse gas emissions, a key
factor in global climate change.
center of excellence in Hyderabad
PerkinElmer has announced plans to establish a state-of-the-art
BioPharma Center of Excellence in Hyderabad. The center which will be
opened in October, 2009, will be the second high-tech
facility recently established by PerkinElmer in India.
The new biopharma center will provide regional PerkinElmer clients and
partners in India with access to established and emerging drug
discovery, pharmaceutical quality assurance, control applications and
technologies, and training facilities and expertise. The Hyderabad
facility will also support focused research efforts in screening and
India among 25 best employers in Asia
BD India, a subsidiary of the global medical technology company, Becton
Dickinson and Company, has been featured as one of the top 25 best
employers in Asia and has also achieved a number12 rank in India
according to the Hewitt Associates’ Best Employers 2009
survey. Hewitt Associates, a global human resource consulting and
outsourcing firm, determines these annual lists after extensive studies
of management practices in leading organizations in India and Asia. BD
India is the only firm in the healthcare segment to have been featured
in this prestigious listing for India.
acquires Veeda Laboratories
ICON, a provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries, has
acquired Veeda Laboratories, a wholly-owned subsidiary of
India’s Veeda Clinical Research Group.
The acquisition adds to ICON Development Solutions’ existing
bioanalytical and immunoassay capabilities, which are delivered through
its laboratory in Manchester, UK, and Prevalere Life Sciences, the
US-based bioanalytical and immunoassay laboratory which ICON acquired
in November 2008.